3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
145
Stomach Neoplasms
22
Triple Negative Breast Neoplasms
21
Inflammatory Breast Neoplasms
14
Carcinoma, Hepatocellular
13
Esophageal Neoplasms
11
Lymphoma, Large B-Cell, Diffuse
7
Neoplasms
6
Pancreatic Neoplasms
5
Urinary Bladder Neoplasms
4
Adenocarcinoma Of Esophagus
4
Testicular Neoplasms
3
Sarcoma
3
Primary Breast Cancer
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Non-Muscle Invasive Bladder Neoplasms
3
Liver Neoplasms
3
Gallbladder Neoplasms
3
Carcinoma, Ductal, Breast
3
Breast Neoplasms, Male
3
Unspecified Adult Solid Tumor, Protocol Specific
2
Recurrence
2
Pathologic Complete Response
2
Neoplastic Cells, Circulating
2
Neoplasms, Germ Cell and Embryonal
2
HER2-negative Breast Cancer
2
Carcinoma, Adenoid Cystic
2
Breast Diseases
2
pCR Rate
1
Women With Primary Breast Cancer
1
Interventions
Panitumumab
1
Oxaliplatin
1
Epirubicin
1
Capecitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Oesophago-gastric Cancer
×
Epirubicin
×
Clear all
NCT00824785
2012-12-11
REAL3
Royal Marsden NHS Foundation Trust
Phase 3
Terminated
574 enrolled